

Amendments to the Specification:

Please amend the Specification as follows:

On page 1, para. 1, please amend the paragraph as follows:

[1] This application claims priority to U.S. Provisional Patent Application 60/560,737
10/373,306, filed February 24, 2003.

On page 3, paragraph 10, please amend the first sentence as follows:

[10] Demegen, Inc. of Pittsburg, PA owns several peptides which are being developed for medical use. One is D2A21 (FAKKFAKKFKKFAKKFAKFAFAF) (SEQ. ID. No. 57) being developed under the trade name DEMEGEL.TM

On page 7, paragraph 28, please amend the last sentence as follows:

Positive controls included non-periodic antimicrobial peptides D2A21 (FAKKFAKKFKKFAKKFAKFAFAF) (SEQ. ID. No. 57) and D4E1 (FKLRAKIKVRLRAKIKL) (SEQ. ID. No. 58).

Please insert the substituted sequence listing after the specification and before the claims. The substituted sequence listing contains 18 pages.